Consequently, GLP-1 RAs not only target obesity—the primary pathophysiologic substrate of OSA—but also provide extensive metabolic benefits, functioning as a pharmacological intervention that connects these interrelated disease processes [137]. This evidence concerns the gene GLP1R and obesity disorder.